BRISBANE, Calif., Jan. 6 /PRNewswire-FirstCall/ -- InterMune, Inc.
(Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, Chief Executive
Officer and President of InterMune, will present at the 27th Annual J.P.
Morgan Healthcare Conference in San Francisco on January 15, 2009 at 1:00 p.m.
To access a live audio webcast of the presentation, investors and other
interested parties may log on to the investor relations page of InterMune's
corporate website at http://www.intermune.com. The company recommends logging
on to the site 15 minutes prior to the start of the presentation in order to
register or download any necessary software.
InterMune is a biotechnology company focused on the research, development
and commercialization of innovative therapies in pulmonology and hepatology.
InterMune has a research and development portfolio addressing idiopathic
pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The
pulmonology portfolio includes the Phase 3 program, CAPACITY, which is
evaluating pirfenidone for the treatment of patients with IPF and a research
program focused on small molecules for pulmonary disease. The hepatology
portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to
as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor
research program, and a research program evaluating a new target in
hepatology. For additional information about InterMune and its R&D pipeline,
please visit http://www.intermune.com.
SOURCE InterMune, Inc.
Jim Goff of InterMune, Inc., +1-415-466-2228,
Web site: http://www.intermune.com